ArticleEuropean journal of pediatrics2025
Liver function changes in pediatric FMF: exploring disease dynamics and therapy impacts.
Article in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Familial Mediterranean fever (FMF) is the most common autoinflammatory disease, with colchicine being the standard treatment. Despite its effectiveness, colchicine has a narrow therapeutic index and potential adverse effects, including gastrointestinal discomfort, neutropenia, and hepatotoxicity. This study aimed to assess the impact of colchicine on liver function tests (LFTs), investigate potential causes of LFT elevations, and monitor the course of liver enzyme abnormalities in children with FMF. Children diagnosed with FMF were included if they had at least one LFT elevation ≥ 2 weeks after starting colchicine and were followed every 3 months. Data collected included demographics, clinical features, MEFV variants, disease severity (ISSF), colchicine dose, laboratory markers, and comorbidities. LFT elevations were categorized as mild, moderate, or severe. Fifty-four patients were included. Most had mild enzyme elevation (94.4%). LFT abnormalities appeared after a median of 46.5 months of colchicine. In 74%, enzymes normalized within a month. Recurrent/persistent LFT elevation occurred in 26 patients; hepatosteatosis and obesity were more common in this group. Forty-three patients were administered colchicine as monotherapy, while four patients were treated with a combination of colchicine and IL-1 inhibitors. Two patients with persistently high LFTs with colchicine during follow-up were switched to anti-IL-1 monotherapy. Five patients without attacks and with normal acute phase reactants were closely monitored without medication. Conclusion: Colchicine-associated LFT elevations were typically mild, transient, and manageable, and it appears to be safe for the liver in pediatric FMF, though ongoing monitoring and further long-term studies are warranted. What is Known: • Liver enzyme elevations are uncommon and typically mild in colchicine-treated pediatric FMF patients. • Elevations of LFT may reflect factors other than colchicine, like infections, obesity, or FMF flares. • A structured algorithm based on study findings may assist in managing LFT elevations.
Indexed as
Identifiers
41114804What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.